Gene therapy trials
FDA's Biological Response Modifiers Advisory Committee will discuss long-term follow-up of patients in gene therapy clinical trials Oct. 24 at 9 a.m.. The committee rejected FDA's initial long-term follow-up proposal, a tiered system based on gene transfer vector, at its April 6 meeting (1"The Pink Sheet" April 16, p. 31). The committee will discuss vector design, manufacture and preclinical studies of lentivirus vectors in gene therapy trials Oct. 25, beginning at 8 a.m. On Oct. 26, committee members will discuss development of a lentivirus vector gene transfer product for people with HIV beginning at 8 a.m. The meeting will be held all three days at the Holiday Inn, Gaithersburg, Md
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth